Rhythm Biosciences Limited announced to confirm that it has appointed Biotem Limited, as the global manufacturer of its ColoSTAT® test-kit. Biotem were chosen following a robust due diligence process to select a manufacturer for the ColoSTAT® test-kit that could execute on Rhythm's ambition to address the global unmet need for the early detection of colorectal cancer. With over 40 years of immunoassay development and manufacturing experience, Biotem has the capability to deliver the optimisation and process validation of the manufacturing procedure and the ability to economically produce large-scale quantities of the ColoSTAT® test-kit. Initial design transfer and the broader core technology transfer is currently underway. It is expected that small-scale manufacturing of ColoSTAT® prototype test-kits will have commenced by the end of the 2020 calendar year. The initial batches of test-kits will undergo quality assurance and ongoing product verification testing by Rhythm. The initial batch will used for testing on cancerous and healthy blood samples, forming Study 6, which is on track for completion by Q3FY'21.